Tas-102
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI)unclassifiedPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Unspecified Childhood Solid Tumor, Protocol Specific cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE City of Hope Medical Center | Phase 2/3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2/3 | BBB |
FILGRASTIM Barbara Ann Karmanos Cancer Institute | Phase 3 | BBB |
Carboplatin Seoul National University Hospital | Phase 2/3 | BBB |
Busulphan City of Hope Medical Center | Phase 2/3 | BBB |
View all 50 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →